

DFCI/BWH @ SABCS 2021

Tuesday, December 7

General Session 1

*10:15 am **GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study**Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A.

11:00 am **GS1-08 CCTGMA.32, a phase III randomized double-blind placebo-controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)**
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey RR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR.

2:00-5:00 Special Session

Trust in Science and Healthcare

Co-Moderator: Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Co-Moderator: Maimah Karmo
Tigerlily Foundation
Stone Ridge, VA

Keynote #1

TBD
Panel 1: Equity in Research and Patient Care
TBD

Patient Advocates

Darcy Burbage, DNP, RN, AOCN
Newark, DE

Na'Diah Smith
Tigerlily Foundation

Keynote #2

TBD

Panel 2: Diversity in Clinical Trials – From Ideation to Implementation COVID Update

Erica Stringer-Reasor, MD
UAB Medicine
Birmingham, AL

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Patient Advocates

Ashley Dedmon, MPH, CHES
Tigerlily Foundation

Ysabel Duron
The Latino Cancer Institute

5:00-6:00 Susan G. Komen® Brinker Awards for Scientific Distinction Lectures

Brinker Award for Scientific Distinction in Basic Science
Carlos Caldas, MD
University of Cambridge
Cambridge, United Kingdom

Brinker Award for Scientific Distinction in Clinical Research
Judy Garber, MD, MPH
Dana Farber Cancer Institute
Boston, MA

Wednesday, December 8

8:00-10:30 Poster Session 1

Spotlight Poster Discussion 1- Endocrine Resistance: Novel mechanisms and emerging new therapies

Chair: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Luca Magnani, PhD
Imperial College London
London, United Kingdom

Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

General Session 2

- 9:45 am **GS2-01. Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer**
O'Shaughnessy J, Stemmer SM, Burris HA, Yap Y-S, Sonke G, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga C, Zarate JP, Chakravarty A, Taran T, Le Gac F, Serra P, Hortobagyi GN.
- ~10:30 am **GS2-04. Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early-stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials**
Bradley R, Braybrooke J, Gray R, Hills RK, Lui Z, Pan H, Peto R, Bergh J, Swain SM, Francis P, Gnani M, Perrone F, Regan MM.
- 11:15 am **GS2-07. Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <**

or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER)

Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Puzstai L, Hortobagyi G.

~11:45 am

GS2-09. Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations

Kubler K, Nardone A, Anand S, Gorvich D, Droog M, Hermida-Prado F, Akshi T, Feit AS, Cohen G, Dackus G, Pun M, Kuang Y, Cha J, Miller M, Gibson WJ, Paweletz CP, Van Allen EM, van Leeuwen FE, Nederlof P, Hollema H, Nguyen Q-D, Mourits MJE, Leshchiner I, Stewart C, Matulonis UA, Zwart W, Maruvka YE, Getz G, Jeselsohn R.

*~12:00 pm

GS2-10. Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

Barroso-Sousa R, Li T, Reddy S, Emens LA, Overmoyer B, Lange P, Dilullo MK, Attaya V, Kimmel J, Winer EP, Mittendorf EA, Tayob N, Tolaney SM.

1:00-3:00 Special Sessions

Re-framing Leadership in Academic Breast Oncology post COVID-19

Co-Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Co-Moderator: Rebecca Dent, MD, MSc
National Cancer Center Singapore
Singapore, Singapore

Learning by leading- lessons learned

Clifford A. Hudis, MD, FACP, FASCO
American Society of Clinical Oncology
Alexandria, VA

Applying the lessons of my mentor to building a successful translational breast program

TBD

Panel Members:

Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

4:00-6:00 Educational Sessions

Triple Negative Breast Cancer: Critical Update on Biology and Management

Moderator: Rita Nanda, MD

University of Chicago
Chicago, IL

Genomic and transcriptomic landscape of TNBC

Zhi-Ming Shao, MD
Fudan University of Shanghai
Shanghai, China

Optimizing the management of early stage TNBC

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Brigham and Women's Cancer Center
Boston, MA

Management of special subtypes of TNBC

Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

6:00-7:30 Spotlight Poster Discussions

Spotlight Poster Discussion 4 - Brain Metastases: Managing LMD / Targeting HER2

Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Patricia Steeg, PhD
National Cancer Institute
Bethesda, MD

Eudocia Lee, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Thursday, December 9

8:00-9:30 Poster Session 3

Spotlight Poster Discussion 8 - Novel therapies for HER2+ disease

Chair: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Optimizing use of HER2 therapies in metastatic HER2+ breast cancer and other subtypes

Priyanka Sharma, MD
University of Kansas Cancer Center
Westwood, KS

HER2 kinase inhibitors: neoadjuvant approaches and mechanisms of resistance

Cristina Saura Manich, MD
Vall d'Hebron University Hospital
Barcelona, Spain

Novel therapies for HER2+ advanced breast cancer

Jo Chien, MD
University California San Francisco
San Francisco, CA

General Session 3

- 11:45 am **GS3-09. Loss of *ASXL1* tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer**
Sudhan DR, Chatterjee S, Kim J, Wang Y, Kandagatla V, Ye D, Lin C-C, Gomez Tejeda Zanudo J, Jain E, Marin A, Servetto A, Lee K-m, Povedano JM, McFadden D, Barrett A, Wagle N, Hanker AB, Arteaga CL.
- 12:00 pm **GS3-10. Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)**
Coombes C, Howell SJ, Krebs MG, Lord S, Kenny LM, Bahl A, Clack G, Ainscow E, Dickinson PA, Fostea R, Mansi J, Palmieri C, Bertelli G, Jeselsohn R, Mitri Z, Gradishar WJ, Sardesai S, O'Shaughnessy J, Ward P, Chalasani P, Lehnert M, Ali S, McIntosh S.
- 3:00 - 4:00 pm **TRANSLATIONAL SCIENCE FORUM**
- HER2 Heterogeneity**
Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Baylor College of Medicine
Houston, TX
- Basic**
Kim RM Blenman, PhD, MS
Yale Cancer Center
Yale University
New Haven, CT
- Heterogeneity in treatment outcomes for HER2+ breast cancer – Clinical management strategies**
Sara M. Tolaney, MD, MPH
Dana Farber Cancer Institute
Boston, MA
- Molecular heterogeneity in HER2+ breast cancer – can outcomes be predicted?**
Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

4:00-6:00 Educational Sessions

Anti-cancer Immune Response

Moderator: Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells

Laurence Zitvogel, MD, PhD
Institut Gustave Roussy
Villejuif, France

Macro and micro: Macrophage and microbiome diversity in the breast cancer microenvironment

Jennifer L. Guerriero, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Optimizing immunotherapy efficacy in the clinic through biomarkers: Advances in single cell and spatial histology analyse
Marleen Kok, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherland

6:00-7:30 Poster Session 4

Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches - Stars at Night Ballroom 1&2

Chair: Kevin Kalinsky, MD, MS
Winship Cancer Institute
Emory University
Atlanta, GA

Rebecca A. Shatsky, MD
UC San Diego Health
San Diego, CA

TBD

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Friday, December 10

8:00-9:30 Poster Session 5

Spotlight Poster Discussion 13 - Novel therapeutics

Chair: Sara M. Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Mafalda Oliveira, MD, PhD
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Heather A. Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

General Session 4

- 11:15 am **GS4-07. The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts**
Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, Simpson L, Vennam S, Khan A, Hardman T, Harmon BE, Couch FJ, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe PF, Nangia J, Lee J, Tseng J, Storniolo AM, Thompson A, Gupta G, Burns R, Veis DJ, DeSchryver K, Zhu C, Matusiak M, Wang J, Zhu SX, Tappenden J, Yi Ding D, Zhang D, Luo J, Jiang S, Varma S, Straub C, Srivastava S, Curtis C, Tibshirani R, Angelo RM, Hall A, Owzar K, Polyak K, Maley C, Marks JR, Colditz GA, Hwang ES, West RB.
- 11:45 am **GS4-09. Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline *BRCA1/2* mutations and high-risk HER-2 negative early breast cancer**
Ganz PA, Bandos H, Spanic T, Friedman S, Müller V, Kümmel S, Delalogue S, Brain E, Toi M, Yamauchi H,

de Dueñas E-M, Armstrong A, Im S-A, Song C, Zheng H, Sarosiek T, Sharma P, Rossi G, Rastogi P, Fielding A, Gelber RD, Campbell C, Garber JE, Geyer Jr CE, Tutt ANJ.

12:30 – 1:30 pm **DEBATE**

RxPONDER: Was it all OFS?

Chair: Harold Burstein MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Pro

Michael Gnant, MD
Medical University of Vienna
Vienna, Austria

Con

Sibylle Loibl, Dr Med
GBG Forschungs GMBH
Hessen, Germany

3:00 – 4:00 pm **Mini Symposia**

The Evolution of Local Therapy in the Genomic Era

Moderator: Tari King, MD
Brigham and Women's Hospital
Boston, MA

Is less (or more) axillary surgery needed in the genomic era?

Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Can genomic risk be used to tailor radiation therapy?

Philip Poortmans, PhD
Iridium Netwerk
Paris, France

6:00 – 8:00 pm **View from the Trenches: What will You do on Monday Morning?**

Moderator: Stephen Johnston, MBBS, ARCP, PhD
The Royal Marsden Hospital
London, United Kingdom

Panel Members

Carlos H. Barrios, MD
Latin American Cooperative Oncology Group (LACOG)
Porto Alegre, Brazil

Thomas Braun, PhD
University of Michigan
Ann Arbor, MI

Javier Cortes, MD, PhD
International Breast Cancer Center
Barcelona, Spain

Erika Hamilton, MD
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Meena Moran, MD
Yale School of Medicine
New Haven, CT

Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Jorge S. Reis-Filho, MD, MRCPATH, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Ivis Febus-Sampayo
SHARE
New York, NY

Alastair Thompson, BSc (Hons), MBChB, MD, FRCSEd, FACS
Baylor College of Medicine
Houston, MD

Posters

Poster Session 1 – Wednesday, December 8th 8-9:30 am	
P1-02-02	Examination of low Her2 expression in breast cancer Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong R, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL
P1-02-09	Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC) De Schepper M, Vincent-Salomon A, Christgen M, Van Baelen K, Tsuda H, Kurozumi S, Brito MJ, Cserni G, Schnitt S, Larsimont D, Kulka J, Fernandez PL, Rodriguez P, Aula A, Mendelez C, Van Bockstal M, Kovacs A, Varga Z, Wesseling J, Bhargava R, Boström P, Franchet C, Zambuko B, Matute G, Berghian A, van Diest P, Oesterreich S, Derksen PWB, Floris G, Desmedt C.
*~P1-04-05	Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer O'Meara TA, Keenan TE, Waks AG, Felt KD, Sharma B, Rodig S, Hughes M, Lin NU, Agudo J, Guerriero JL, McAllister SS, Mittendorf E, Tolaney S.
*P1-04-09	Essential role for MUC1-C in chronic activation of cytosolic nucleotide sensing and the type I interferon pathway in triple-negative breast cancer Yamashita N, Fushimi A, Morimoto Y, Bhattacharya A, Long M, Liu S, Kufe D.
*~P1-04-13	Generation and validation of an estrogen receptor signaling (ERS) gene panel that inversely correlates with antigen presentation and T cell infiltration and activity in hormone receptor positive (HR+) breast cancer Goldberg JS, Cui X, Shimada K, McAllister S, Tolaney S, Waks A, Jeselsohn R, Guerriero J, Agudo J, Mittendorf E.
P1-08-35	Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199 Klar N, Gray RJ, Adams S, Sparano JA, Goldstein LJ, DeMichele AM, Wolff AC, Davidson NE, George W Sledge GW, Badve SS.

*P1-09-06	Insulinemic potential of diet and risk of total and subtypes of breast cancer among US women Romanos-Nanclares A, Willett WC, Rosner BA, Tamimi RM, Tabung FK, Holmes MD, Chen WY, Eliassen AH.
P1-18-02	Sacituzumab Govitecan, in combination with the PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (mTNBC): translational investigation Bardia A, Coates JT, Spring L, Sun S, Juric D, Thimmiah N, Partridge A, Peppercorn J, Parsons H, Wander S, Pierce K, Attaya V, Fitzgerald D, Lormil B, Shellock M, Nagayama A, Bossuyt V, Moy B, Tolaney SM, Ellisen L.
P1-18-12	Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) Coombes C, Howell SJ, Krebs MG, Lord S, Kenny LM, Bahl A, Clack G, Ainscow E, Dickinson PA, Fostea R, Mansi J, Palmieri C, Bertelli G, Jeselsohn R, Mitri Z, Gradishar WJ, Sardesai S, O'Shaughnessy J, Ward P, Chalasani P, Lehnert M, Ali S, McIntosh S.
P1-18-13	Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials Isaacs C, Mahtani R, Lynce F, Sleckman B, Castellon A, Kalmadi S, Theall KP, Huang X, Bananis E, Rugo HS.
P1-22-04	Decision aids and risk prediction models to support decision making about DCIS treatment: A systematic literature review Schmitz RSJM, Wilthagen E, van Duijnhoven F, van Oirsouw M, Verschuur E, Lynch T, Punglia RS, Hwang S, Wesseling J, Schmidt MK, Bleiker E, Engelhardt EG,
~P1-23-01	Male breast cancer- a 20-year multi-center experience Zheng G, Wang H, Liu F-Y, Leone JP.
Poster Session 2 – Wednesday, December 8th 6–7:30 pm	
P2-01-15	Developing highly sensitive high NGS data efficient ctDNA detection assays for breast cancer surveillance Fu A, Cui W, Ton MV, Wang K, Gu W, Li T, Parsons HA, Liu MC, Sledge GW.
P2-07-02	Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC) Velimirovic M, Gerratana L, Davis AA, Hensing WL, Clifton K, Shah AN, D'Amico P, Dai CS, Denault EN, Ma CX, Wander SA, Juric D, Cristofanilli M, Chabner BA, Bardia A.
*~P2-07-03	Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancer Waks AG, Huang Y, Hether T, Ogayo ER, Kadel S, Alberti J, Tolaney SM, Krop IE, Divakar P, Metzger O, O'Donnell ML.
*~P2-07-13	High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer Guerriero JL, Baker GJ, Lin J-R, Chen Y-A, Pastorello R, Vallius T, Davis J, Yapp C, Church SE, Miller E, Färkkilä A, Vinayak S, Telli ML, Fulci G, D'Andrea A, Shapiro GI, Tolaney SM, Santagata S, Sorger PK, Mittendorf EA.

*~P2-09-03	Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden Bychkovsky BL, Lo M-T, Yussuf A, Horton C, Hemyari P, LaDuca H, Garber JE, Rana HQ.
*~P2-10-01	Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with triple-negative breast cancer Leone JP, Graham N, Leone J, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Vallejo CT, Winer EP, Lin NU, Tayob N.
P2-11-21	Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model Hughes E, Bernhisel R, Pederson H, Probst B, Simmons T, Wagner S, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, Gordon OK, Klemp J, Mukherjee S, Offit K, Olopade F, Vijai J, Weitzel J, Whitworth P, Yehia L, Kurian A, Robson M, Slavin TP, Gutin A, Lanchbury JS.
*~P2-12-18	A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer Lynce F, Yeh ED, Regan MM, Qin L, Bay CP, Krop I, Harrison BT, Nakhlis F, Bellon J, Overmoyer B.
*~P2-13-02	Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis Weiss A, Waks AG, Laws A, Tolaney SM, Winer EP, Mittendorf EA, Partridge AH, King TA.
*P2-13-05	Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC) Lin NU, Lueftner D, Brufsky AM, Tolaney SM, Melisko ME, Holmes FA, Awada A.
*P2-13-25	A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer Krop I, Hamilton E, Jung KH, Modi S, Kalinsky KM, Phillips G, Shi R, Monemi S, Mamounas M, Saad O, Choerng V, Commerford R, Cho E, Ungewickell A, LoRusso P.
~P2-14-17	A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC) Isakoff SJ, Tung NM, Yin J, Tayob N, Parker J, Rosenberg J, Bardia A, Spring L, Park H, Collins M, Barry WT, Severgnini M, Peterkin D, Tolaney SM.
*~P2-14-18	A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer Garrido-Castro AC, Graham N, Bi K, Park J, Fu J, Keenan T, Richardson ET, Pastorello R, Lange P, Attaya V, Wesolowski R, Sinclair N, Lucas Z, Lo S, Tung N, Faggen M, Kaufman PA, Block CC, Briccetti F, Toke M, Chen W, Wucherpfennig K, Marx S, Tian Y, Agudo J, Guerriero JL, Schnitt S, Lin NU, Winer EP, Mittendorf EA, Tayob N, Van Allen E, Tolaney SM.
Ongoing Trials Poster Session 1 – Wednesday, December 8th 6–7:30 pm	
OT1-12-02	Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab Miller K, Emens LA, Tolaney SM, Hurvitz SA, Hamilton E, Paton V, Hannah A, Boni V.
~OT1-13-01	HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (trial in progress) Hamilton E, Carey L, Ramos J, Chen Y, Krop I.
*OT1-14-02	Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first line (1L), human epidermal growth factor receptor 2-positive

	<p>(HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 Tolaney SM, Barroso-Sousa R, Jiang Z, Park YH, Rimawi M, Saura C, Schneeweiss A, Toi M, Yu T, Shetty J, Herbolsheimer P, Loibl S.</p>
*OT1-19-01	<p>The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research Wagle N, Painter C, Anastasio E, McGillicuddy M, Jain E, Hernandez TG, Tomson BN, Thomas B, Abravanel D, Kim D, Balch S, Damon AL, Shah S, Ramos R, Sosa D, Small I, Nguyen C, Winnicki S, Cusher T, Chastain P, Dunphy M, Gomez Tejeda Zanutto J, Tsegai N, Sterlin L, Ulysse UF, Boykin I, Alao O Golub TR.</p>
	<p>Poster Session 3 – Thursday, December 9th 8–9:30 am</p>
P3-03-04	<p>Challenges of achieving high image quality on breast MRI for quantitative measurements in the I-SPY 2 TRIAL Bareng TJ, Gibbs JE, Onishi N, Newitt DC, LeStage B, I-SPY 2 TRIAL Imaging Working Group, I-SPY 2 TRIAL Coordinators, HyltonNM.</p>
*~P3-04-03	<p>The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study Laws A, Katlin F, Hans M, Graichen M, Kantor O, Minami C, Bychkovsky B, Pace L, Scheib R, Garber J, King T.</p>
*~P3-08-01	<p>Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer Santos K, Jin Q, Miller PG, Patel A, Kirkner GJ, Files JL, Hughes ME, Stokes SM, Tayob N, Stover DG, Gibson CJ, Winer EP, Lin NU, Garber JE, Parsons HA.</p>
*~P3-09-01	<p>A ubiquitination cascade regulating the integrated stress response and survival in carcinomas Cervia LD, Shibue T, Gaeta B, Borah AA, Leung L, Li N, Dumont N, Gonzalez A, Bick N, Kazachkova M, Dempster JM, Krill-Burger JM, Piccioni F, Udeshi N, Olive ME, Carr SA, Root DE, McFarland JM, Vazquez F, Hahn WC.</p>
P3-09-18	<p>The association between genomic alterations and body mass index in patients with early breast cancer Nguyen H-L, Geukens T, Maetens M, Van Baelen K, De Schepper M, Leduc S, Isnaldi E, Aparicio S, Borg A, Brock J, Broeks A, Caldas C, Green A, Khout H, Jórunn E, Knappskog S, Krishnamurthy S, Lakhani S, Langerod A, Martens JWM, Murphy L, Nik-Zaina S, Purdie C, Rakha E, Richardson A, Salomon A, Simpson P, Sotiriou C, Span P, Tan BK, Thompson A, Tommasi S, Van de Vijver M, Van Laere S, Viari A, Floris G, Biganzoli E, Richard F, <i>Desmedt C.</i></p>
*~P3-12-01	<p>Regular aspirin use, breast tumor characteristics and long-term breast cancer survival Peng C, Holmes MD, Wang T, Harris A, Chen W, Brantley K, Heng YJ, Bret-Mounet VC, Baker GM, Rosner B, Willett W, Tamimi R, Eliassen AH.</p>
*~P3-12-02	<p>Loss of PTEN expression, PIK3CA mutations, and breast cancer survival in the Nurses' health studies Wang T, Heng YJ, Baker GM, Bret-Mounet VC, Hankinson SE, Holmes MD, Chen WY, Willett WC, Rosner BA, Tamimi RM, Eliassen AH.</p>
P3-12-19	<p>Associations of alcohol consumption with benign breast tissue composition Yaghjian L, Austin-Datta R, Heng YJ, Baker G, Rosner B, Tamimi R.</p>
~P3-12-32	<p>Long-term outcomes among young Saudi women with breast cancer Aboualkhair OA, Omair A, Masuadi E, Alamri G, Aljehani A, Alkushi A, Partridge A.</p>
P3-15-03	<p>Imaging and invasive lobular carcinoma: A survey study conducted by the lobular breast cancer alliance Hutcheson LB, Axelrod J, Fitzwater CL, Jochelson MS, Joergensen GH, Langdon T, Levine JK, Metzger O, Mitchell-Daniels M, Neilsen BF.</p>

P3-17-03	<p>Raising the level of cancer care around the world: The feasibility and perceived benefit of a virtual breast tumor board</p> <p>Dempsey N, Chiec L, Lodder M, Shonkwiler E, Haines K, Mahtani R, Gradishar W, Buchholz T, O'Dea A, Wolmark N, Hurvitz S, O'Shaughnessy J, Jochelson M, Butler R, Mamounas E, Vicini F, Pegram M, Shah C, King T, O'Regan R, Morrow M.</p>
*~P3-18-05	<p>Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial</p> <p>Weiss A, Li T, Desai NV, Tung NM, Tayob N, King TA, Winer EP, Mittendorf EA, Waks AG.</p>
<p>Ongoing Trials Poster Session 2 – Thursday, December 9th 6–7:30 pm</p>	
~OT2-01-02	<p>First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer</p> <p>Patnaik A, Barve M, Bhave M, Subbiah V, Atwal S, Sharma K, Scheffold C, Wetmore C, Shapiro G.</p>
OT2-11-05	<p>SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy</p> <p>Bidard F-C, Kalinsky K, Cristofanilli M, Bianchini G, Chia SKL, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, Walding A, Huang Bartlett C, Turner NC.</p>
~OT2-17-01	<p>Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK 4/6 inhibitor</p> <p>Brufsky A, Linden H, Rugo H, Vogel C, O'Shaughnessy JA, Getzenberg RH, Barnette KG, Rodriguez D, Steiner MS, Mayer E.</p>
*OT2-26-01	<p>Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast12</p> <p>Lin NU, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Ocroft E, Anand S, Walker G, Harbeck N.</p>
<p>Poster Session 4 – Thursday, December 9th 6–7:30 pm</p>	
P4-01-04	<p>FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer</p> <p>Li Y, Qiu X, Wang X, Liu H, Geck R, Tewari A, Chow K-H, Xiao T, Cejas P, Nguyen Q-D, Long H, Liu SX, Toker A, Brown M.</p>
~P4-01-06	<p>Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i)</p> <p>Gomez Tejada Zanudo J, Barroso-Sousa R, Jain E, Buendia-Buendia J, Li T, Tayob N, Rees R, Pereslete A, Ferreira AR, Abravanel DL, Helvie K, Partridge AH, Overmoyer B, Winer EP, Wagle N, Tolaney SM.</p>
*~P4-04-06	<p>Integrative analysis of single-cell transcriptomic and spatial profiles characterized distinct tumor microenvironment phenotypes in hormone receptor positive (HR+) breast cancer</p> <p>Shimada K, Cui YX, Goldberg JS, Pastorello R, Davis J, Vallius T, Kania L, Patel A, Moore M, Ogayo ER, Dillon D, Sorger PK, Guerriero JL, Mittendorf EA..</p>
*~P4-09-01	<p>Incidence of patient-reported fatigue developing in patients receiving palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer</p>

	Rahman SA, Erica L Mayer EL, Poort H, Schrag D, Tung SC, Zhou ES, Wiley A, Finkelstein L, Elguenaoui E, Nolan M, Joffe H.
~P4-10-01	Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) Naughton MJ, Zahrieh D, Gnant M, Zdenkowski N, Lemieux J, Mao JJ, Bjelic-Radisic V, Shinn E, Balic M, Thomssen C, Neisel J, Ruiz-Echarri M, Loibl S, Isaacs C, Cameron D, Carrasco FMH, Goetz M, Wette V, Werutsky G, Rugo H, Vetter M, Tseng L-M, Miller K, Fitzal F, Gil Gil JM, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law E, Partridge A, Carey L, Zoroufy A, Dueck A, Hlauschek D, DeMichele A, Mayer E.
P4-10-02	Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI.
P4-11-01	Development of a clinico-bio-behavioral model for cancer-related fatigue (CRF) incorporating inflammatory biomarkers and proteomic data Di Meglio A, Christodoulidis S, Soldato D, Noce AD, Presti D, Havas J, Dubuisson F, Pistilli B, Camara-Clayette V, Charles C, Ganz PA, Bower J, Partridge AH, Jacquet A, Everhard S, Boyault S, André F, Courneade P-H, Michiels S, Pradon C, Vaz-Luis I.
P4-11-02	Prevalence and impact of fertility concerns in young women with breast cancer Mannion S, Higgins A, Stewart EA, Khan Z, Shenoy C, Larson N, Nichols HB, Su HI, Partridge AH, Couch FJ, Olson JE, Ruddy K.
P4-11-20	Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study Lambertini M, Massarotti C, Havas J, Pistilli B, Martin A-L, Jacquet A, Coutant C, Coussy F, Dhaini Merimeche A, Lerebours F, Tredan O, Jouannaud C, Rigal O, Fournier M, Soulie P, Franzoi MA, Del Mastro L, Partridge AH, Andre F, Vaz-Luis I, Di Meglio A.
P4-12-01	Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton M, Pfeiler G, Gelmon K, Mayer I, Egle D, Zoppoli G, Traina T, Jiménez MM, Novoa SA, Haddad T, Chan A, Ring AE, Wolff A, Lorenz JJP, Sabanathan D, Burstein H, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerria M, Foukakis T, Novik Y, Rubovszky G, Muehlbacher K, Metzger O, Goulioti T, Law E, Partridge A, Carey L, Zoroufy A, Hlauschek D, Fesl C, Mayer E, Gnant M.
Poster Session 5 – Friday, December 10th 8–9:30 am	
P5-13-05	Multiplex spatial systems analysis of responses to spatially separate nanoliter doses of drug predicts systemic immune-modulating combination treatments in breast cancer Tatarova Z, Blumberg DC, Coussens LM, Mills GB, Jonas O, Gray JW.
*~P5-13-15	High dimensional flow cytometric analysis of the peripheral immune profile and response to HER2-targeted antibody therapy Ogayo ER, Waks A, Rogers W, Ionita M, Adigwe K, Alberti J, Kadel S, Moore J, King T, Krop I, Tolancy S, Winer E, Guerriero J, Mittendorf E..
P5-14-08	Effectiveness of palbociclib plus letrozole vs letrozole in US Hispanic and African American patients with metastatic breast cancer: Flatiron database analysis Rugo H, Lynce F, Liu X, Li B, McRoy L, Isaacs C.
P5-16-01	Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) Loibl S, Tolancy SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky A, Kalinsky KM,

	Cortes J, O'Shaughnessy J, Carey LA, Gianni L, Diéras V, Shi L, Gharaibeh M, Preger L, Moore L, Phan S, Piccart M.
P5-16-06	A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer Yap TA, Basu C, Goldman JW, Gordon M, Hamilton E, Kelly A, Liu F, Moreau AR, Neumann H, Papadopoulos K, Rugo HS, Shapiro GI, Vinayak S, Zhou L, Jhaveri K.
P5-16-15	Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) Cortés J, Bardia A, Loirat D, Tolaney SM, Punie K, Oliveira M, Hurvitz SA, Brufsky A, Sardesai S, Kalinsky KM, Traina T, Hamilton E, O'Shaughnessy J, Diéras V, Carey LA, Piccart M, Loibl S, Rugo HS, Zhu Y, Phan S, Gianni L.
P5-17-05	A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer Juric D, Bedard PL, Cervantes A, Gambardella V, Oliveira M, Saura C, Kalinsky KM, Hamilton E, Italiano A, Krop IE, Schmid P, Turner NC, Varga A, Royer-Joo S, Hutchinson KE, Schutzman JL, Jhaveri KL.
P5-18-09	Halt-d: A randomized open label phase 2 study of crofelemer for the prevention of chemotherapy induced diarrhea (cid) in patients with breast cancer receiving trastuzumab, pertuzumab, and a taxane Pohlmann PR, Graham D, Wu T, Ottaviano Y, Mohebtash M, Kurian S, McNamara D, Lynce F, Warren R, Dilawari A, Rao S, Mainor C, Swanson N, Tan M, Isaacs C, Swain SM.
P5-19-03	What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials? Cui W, Phillips K-A, Francis PA, Loi S, Anderson RA, Partridge AH, Keogh LA.

Spotlight Sessions

	Spotlight Session 1 – Wednesday, December 8th 8-9:30 am
PD1-05	Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer Liu CC, Qin L, De Angelis C, Nanda S, Pereira R, Shea MJ, Nardone A, Jeselsohn R, Cohen O, Wagle N, Liu Z, Rimawi MF, Osborne CK, Schiff R, Fu X.
PD1-08	Esr1 mutant breast cancers show elevated basal cytokeratins and immune activation Li Z, Wu Y, Meginn O, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Sartorius CA, Miller L, Rosenzweig M, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S.
	Spotlight Session 2 – Wednesday, December 8th 8-9:30 am
~PD2-09	Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial Gnant M, Dueck AC, Frantal S, Martin M, Burstein H, Greil R, Fox P, Wolff AC, Chan A, Winer E, Singer C, Miller K, Colleoni M, Naughton M, Rubovszky G, Bliss J, Mayer IA, Steger GG, Nowecki Z, Hahn O, Wolmark N, Rugo H, Pfeiler G, Fohler H, Metzger O, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A*, Mayer EL.

	Spotlight Session 4 – Wednesday, December 8th 6-7:30 pm
PD4-02	Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study Murthy RK, O'Brien B, Berry DA, Singareeka-Raghavendra A, Gule Monroe M, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikawa A, Ferguson S, de Groot JF, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin NU, Stringer-Reasor E.
*~PD4-04	Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB) Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien AJ, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E.
*~PD4-05	Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM) Kabraji S, Ni J, Sammons S, Van Swearingen AED, Wang Y, Pereslete AM, Hsu L, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JZ, Lin NU.
	Spotlight Session 5 – Wednesday, December 8th 6-7:30 pm
PD5-06	Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy A-S, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Córdoba O, Teixeira L, Clatot F, Punie K, Graffeo Galbiati R, Dieci MV, Pérez-Fidalgo A, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmaña J, Partridge AH, Azim HAJ, Demeestere I, Lambertini M.
	Spotlight Session 6 – Wednesday, December 8th 6-7:30 pm
~PD6-02	The metastatic breast cancer project - Expanding the clinical, genomic, and transcriptomic landscape of metastatic breast cancer through patient-partnered research Jain E, Kim D, Gomez Tejada Zanudo J, Balch S, McGillicuddy M, Tomson BN, Hernandez TG, Thomas BS, Abravanel DL, Shah S, Ramos R, Sosa D, Small I, Sterlin L, Winnicki S, Nguyen C, Dunphy M, Anastasio E, Golub TR, Painter CA, Wagle N.
*~PD6-03	Spatio-molecular dissection of the breast cancer metastatic microenvironment Abravanel DL, Klughammer J, Blosser T, Goltsev Y, Jiang S, Bai Y, Murray E, Alon S, Cui Y, Goodwin DR, Sinha A, Cohen O, Slyper M, Ashenberg O, Dionne D, Jané-Valbuena J, Porter CBM, Segerstolpe A, Waldman J, Vigneau S, Helvie K, Frangieh A, DelloStritto L, Patel M, We J, Pfaff K, Cullen N, Lako A, Turner M, Wakiro I, Napolitano S, Kanodia A, Ortiz R, MacKichan C, Inga S, Chen J, Thorner AR, Rotem A, Rodig S, Chen F, Boyden ES, Nolan GP, Zhuang X, Rozenblatt-Rosen O, Johnson BE, Regev A, Wagle N.
	Spotlight Session 7 – Thursday, December 9th 8-9:30 am
PD7-06	Trends in surgical resection for stage IV breast cancer: Less surgery more systemic treatment Douglas SR, Lizarraga I, Boughey JC, Weiss A, Hunt K, Dickson-Witmer D, Subhedar PD, Park KU, Zhao B, Blair S.
PD7-07	Surgical management and contralateral breast cancer risk in women with a history of radiation therapy for Hodgkin lymphoma: Results from a population-based cohort Eisenberg ER, Weiss A, Prakash I, Skamene S, Basik M, Boileau JF, Ajjamada L, Pollak M, Wong SM.
	Spotlight Session 9 – Thursday, December 9th 8-9:30 am
*~PD9-01	Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial

	Kantor O, Burstein HJ, King T, Shak S, Russell C, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EA.
*PD9-02	Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study Lynce F, Mainor C, Geng X, Jones G, Schlam I, Wang H, Feger U, Donahue R, Toney N, Jochems C, Schlom J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Dilawari AA, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Swain SM, Parsons HA, Pohlmann P, Isaacs C.
PD9-03	Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106) Ma CX, Anurag M, Dockter T, Hoog J, Fernandez-Martinez A, Fan C, Gibbs R, Sanati S, Vij K, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken TJ, Wang Y, Leitch AM, Unzeitig GW, Weiss A, Winer EP, Hunt K, Partridge AH, Carey LA, Perou CM, Ellis MJ, Suman V.
	Spotlight Session 13 – Friday, December 10th 8-9:30 am
*~PD13-10	Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Sella T, Zheng Y, Rosenberg SM, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Carey LA, Winer EP, Partridge AH.
	Spotlight Session 14 – Friday, December 10th 8-9:30 am
PD14-08	Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status Hills RK, Oesterreich S, Metzger O, Dabbs D, Pan H, Braybrooke J, Gray R, Peto R, Bradley R, Straiton E, Berry R, Rea D, Cameron D, Cuzick J, Regan M, Dowsett M, Sestak I, Bergh J, Swain SM, Bartlett J.